Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28973531 | 0.93 | CA2 (0.50) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL26622845 | 0.86 | CA2 (0.50) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL6239517 | 0.85 | CA2 (0.46) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL183036 | 0.84 | CYP3A4 (0.50) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL25236891 | 0.83 | CYP3A4 (0.55) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL28830574 | 0.83 | CA2 (0.45) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL25235809 | 0.83 | CYP3A4 (0.55) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL2440937 | 0.83 | CYP3A4 (0.55) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL29002875 | 0.83 | CA2 (0.45) | CA2CA1CYP3A4TSHRTDP1 | |
| SCHEMBL25236063 | 0.83 | CYP3A4 (0.55) | CA2CA1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20100286102-A1 | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage | SYMRISE GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-1816998-A1 | FORMULATIONS COMPRISING CERAMIDES AND/OR PSEUDOCERAMIDES AND (ALPHA-)BISABOLOL FOR COMBATING SKIN DAMAGE | Symrise GmbH & Co. KG (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006053912-A1 | FORMULATIONS COMPRISING CERAMIDES AND/OR PSEUDOCERAMIDES AND (ALPHA-)BISABOLOL FOR COMBATING SKIN DAMAGE | SYMRISE GMBH & CO. KG (DE) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286102-A1 | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage | CERT1, CERS2, SGMS1 | CA2 1247/4885CA1 2143/4885CYP3A4 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.